Q32 Bio Inc (QTTB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Q32 Bio Inc (QTTB) has a cash flow conversion efficiency ratio of 0.229x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.23 Million) by net assets ($-18.45 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Q32 Bio Inc - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Q32 Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Q32 Bio Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Q32 Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Q32 Bio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shivalik Rasayan Limited
NSE:SHIVALIK
|
0.010x |
|
Genetec Technology Bhd
KLSE:0104
|
-0.110x |
|
Laurion Mineral Exploration Inc
V:LME
|
-0.278x |
|
Global Knafaim Leasing Ltd
TA:GKL
|
0.027x |
|
Bioptik Technology
TWO:4161
|
0.055x |
|
Dongwoo Farm To Table Co.Ltd
KQ:088910
|
0.052x |
|
Century Lithium Corp.
V:LCE
|
-0.010x |
|
Major Cineplex Lifestyle Leasehold Property Fund
BK:MJLF
|
0.015x |
Annual Cash Flow Conversion Efficiency for Q32 Bio Inc (2016–2024)
The table below shows the annual cash flow conversion efficiency of Q32 Bio Inc from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Q32 Bio Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $5.67 Million | $-67.72 Million | -11.932x | -11786.26% |
| 2023-12-31 | $-182.92 Million | $-18.68 Million | 0.102x | +21.81% |
| 2022-12-31 | $-130.71 Million | $-10.96 Million | 0.084x | +112.96% |
| 2021-12-31 | $169.65 Million | $-109.75 Million | -0.647x | -34.41% |
| 2020-12-31 | $196.00 Million | $-94.33 Million | -0.481x | -36.19% |
| 2019-12-31 | $258.51 Million | $-91.36 Million | -0.353x | -63.04% |
| 2018-12-31 | $196.35 Million | $-42.56 Million | -0.217x | -428.91% |
| 2017-12-31 | $98.31 Million | $6.48 Million | 0.066x | +105.83% |
| 2016-12-31 | $7.50 Million | $-8.48 Million | -1.131x | -- |
About Q32 Bio Inc
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti"interleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking … Read more